Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 80Years
All Genders
ID06773663

Evaluation of Biodistribution, Dosimetry, Diagnostic and Surgery-guiding Ability of Al18F-NOTA-Pentixafor PET Imaging for Patients With Primary Aldosteronism: A Prospective, Single-center Study

Led by Peking Union Medical College Hospital · Updated on 2025-02-26

150

Participants Needed

1

Research Sites

21 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Primary aldosteronism (PA) is a leading cause of secondary hypertension and affects millions worldwide. This study evaluates a new imaging method, Al18F-NOTA-Pentixafor PET/CT, which targets a receptor called CXCR4 found on aldosterone-producing adenomas. Researchers aim to assess how this imaging works, its safety, and how well it helps guide surgery decisions for patients with PA in a prospective, single-center trial. Participants will receive an intravenous injection of the Al18F-NOTA-Pentixafor tracer. After injection, PET and CT scans will be performed within 45-90 minutes to visualize CXCR4-positive lesions. The study will monitor tracer distribution and radiation dose and track diagnostic accuracy and surgical outcomes guided by this imaging over 1 to 1.5 years, including a 6-month follow-up after surgery. Throughout the study, participants will undergo safety assessments from the time of tracer injection up to 24 hours afterward. Researchers will also evaluate diagnostic accuracy based on clinical or pathological diagnoses at 6 months post-imaging and surgical results. Additional measurements include organ uptake of the tracer and radiation dose, monitored up to 6 months after study completion. Participation involves imaging procedures, follow-up visits, and adherence to contraception requirements when applicable.

CONDITIONS

Brief Title

Application of Al18F-NOTA-Pentixafor PET/CT for Primary Aldosteronism

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with adrenal masses suspected to be aldosterone-producing adenomas based on routine imaging or clinically diagnosed primary aldosteronism patients requiring subtyping
  • Signed written informed consent, with willingness and ability to comply with study procedures
  • Female participants must be surgically sterilized or postmenopausal for over a year; if not, reliable contraception is required
  • Male participants must use reliable contraception during the study and refrain from sperm donation
Not Eligible

You will not qualify if you...

  • Severe neurological disorders or significant diseases affecting gastrointestinal, cardiovascular, hepatic, renal, hematological, oncological, endocrine, respiratory, or immune systems
  • Diagnosis of claustrophobia
  • History of drug abuse or alcohol dependence
  • Pregnant or breastfeeding women
  • Poor venous access precluding repeated venipuncture
  • Use of experimental drugs or devices within one month prior to the study
  • Any condition deemed by investigators to pose potential harm or jeopardize participant safety

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Diagnostic Evaluation

Duration - Single day procedure with imaging 45-90 minutes post-injection

Participants receive an intravenous injection of Al18F-NOTA-Pentixafor followed by PET/CT imaging to assess biodistribution, dosimetry, and diagnostic accuracy for primary aldosteronism.

1 visit (in-person)

Long-term Monitoring

Duration - Up to 1 to 1.5 years from enrollment

Participants are monitored for safety and surgical outcomes guided by Al18F-NOTA-Pentixafor PET/CT, including a 6-month follow-up after surgery if applicable.

Follow-up visits over 6 months after imaging and surgery as applicable

Trial Site Locations

Total: 1 location

1

Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College

Beijing, China

Actively Recruiting

Loading map...

Research Team

X

Xinchun Yan, PhD

L

Li Huo, MD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

DIAGNOSTIC

Number of Arms

1

Similar Trials

68Ga-Pentixafor PET/CT Versus Adrenal Vein Sampling in Diagn...

Primary Aldosteronism

Actively Recruiting

1 location

Features of the Gut Microbiota in Patients With Critical Chr...

Essential Hypertension

Actively Recruiting

50 locations

A Multicenter, Randomized, Double-blind, Placebo-controlled ...

Primary Aldosteronism

Actively Recruiting

2 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here